Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. [electronic resource]
Producer: 20170911Description: 284-290 p. digitalISSN:- 1502-7708
- Adalimumab -- therapeutic use
- Adolescent
- Adult
- Child
- Female
- Finland
- Follow-Up Studies
- Humans
- Inflammatory Bowel Diseases -- classification
- Infliximab -- therapeutic use
- Male
- Middle Aged
- Prognosis
- Proportional Hazards Models
- Recurrence
- Remission Induction
- Retrospective Studies
- Risk Factors
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.